GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Q1 FY27 Consolidated Revenue Rs. 2,149.77 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Aug 2026, 02:05 PM IST  ·  BSE ID: f1feadc2-3fa3-4b4d-ae71-61262a26fef5
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has approved and released its financial results for the first three months of the current financial year.
🤖 AI Summary
  • Alembic Pharmaceuticals' Board approved Q1 FY27 Consolidated and Standalone Unaudited Financial Results on August 4, 2026.
  • Consolidated Revenue from Operations for Q1 FY27 was Rs. 2,149.77 Crores, up from Rs. 1,710.72 Crores YoY.
  • Consolidated Profit for the Period after non-controlling interests for Q1 FY27 was Rs. 173.07 Crores, up from Rs. 154.38 Crores YoY.
  • Standalone Revenue from Operations for Q1 FY27 reached Rs. 1,868.06 Crores, compared to Rs. 1,494.17 Crores YoY.
  • Standalone Profit for the Period for Q1 FY27 stood at Rs. 196.96 Crores, an increase from Rs. 103.52 Crores YoY.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations (Q1 FY27)
2,149.77 Rs. in Crores
25.66%
Consolidated Profit for the Period after non-controlling interests (Q1 FY27)
173.07 Rs. in Crores
12.10%
Standalone Revenue from Operations (Q1 FY27)
1,868.06 Rs. in Crores
25.02%
Standalone Profit for the Period (Q1 FY27)
196.96 Rs. in Crores
90.26%
🏢 How This Affects the Company
📈
Business Impact
The increase in consolidated revenue from operations suggests stronger sales performance, potentially indicating growth in product demand or market penetration.
💰
Financial Impact
Higher consolidated and standalone profits for the period, alongside increased revenue, indicate improved financial performance and profitability during the quarter.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results reflect the company's financial health and operational performance for the quarter ended June 30, 2026.
🔍
Management Signal
The approval and release of the unaudited financial results signal routine compliance and transparency in reporting the company's performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q2 FY27 financial results — assess sustained revenue and profit growth.
Management commentary on segment performance and future outlook.
Analyst calls or investor presentations for deeper insights into results.
LOW RISK The filing reports positive financial results and does not introduce new risks.
💡 Investor Takeaway
Alembic Pharmaceuticals' Q1 FY27 consolidated revenue from operations rose to Rs. 2,149.77 Crores from Rs. 1,710.72 Crores in Q1 FY26. Consolidated profit after non-controlling interests increased to Rs. 173.07 Crores from Rs. 154.38 Crores YoY, demonstrating growth.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from Operations increased to Rs. 2,149.77 Crores in Q1 FY27 from Rs. 1,710.72 Crores in Q1 FY26.
  • Standalone Profit for the Period grew to Rs. 196.96 Crores in Q1 FY27 from Rs. 103.52 Crores in Q1 FY26.
📅 Company Track Record
Alembic Pharma's Q1 FY27 consolidated revenue of Rs. 2,149.77 Crores follows previous reporting of Rs. 2,150 Crores for Q1 FY27, showing a consistent trend. The reported PAT of Rs. 173.07 Crores for Q1 FY27 also aligns with previously indicated Q1 FY27 PAT growth of 12% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q1 FY27?
Alembic Pharmaceuticals reported consolidated Revenue from Operations of Rs. 2,149.77 Crores for the quarter ended 30th June, 2026.
What was Alembic Pharmaceuticals' consolidated profit for Q1 FY27?
Consolidated Profit for the Period after non-controlling interests for Alembic Pharmaceuticals was Rs. 173.07 Crores in Q1 FY27.
How did Alembic Pharmaceuticals' standalone revenue perform in Q1 FY27?
Alembic Pharmaceuticals' Standalone Revenue from Operations for the quarter ended 30th June, 2026, was Rs. 1,868.06 Crores.
What was the standalone profit for Alembic Pharmaceuticals in Q1 FY27?
The Standalone Profit for the Period for Alembic Pharmaceuticals in Q1 FY27 was Rs. 196.96 Crores.
When did Alembic Pharmaceuticals' Board Meeting for Q1 FY27 results conclude?
The Board Meeting for Alembic Pharmaceuticals held on August 4, 2026, commenced at 12:00 noon and concluded at 1:55 p.m.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.